- Home
- PLX vs MIMI Comparison
PLX vs MIMI Comparison
Compare PLX & MIMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- MIMI
- Stock Information
- Founded
- PLX 1993
- MIMI 2018
- Country
- PLX United States
- MIMI Hong Kong
- Employees
- PLX N/A
- MIMI N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- MIMI
- Sector
- PLX Health Care
- MIMI
- Exchange
- PLX Nasdaq
- MIMI NYSE
- Market Cap
- PLX 160.2M
- MIMI 139.9M
- IPO Year
- PLX 1998
- MIMI 2025
- Fundamental
- Price
- PLX $2.87
- MIMI $4.20
- Analyst Decision
- PLX Strong Buy
- MIMI
- Analyst Count
- PLX 1
- MIMI 0
- Target Price
- PLX $15.00
- MIMI N/A
- AVG Volume (30 Days)
- PLX 753.1K
- MIMI 38.1K
- Earning Date
- PLX 05-09-2025
- MIMI 01-01-0001
- Dividend Yield
- PLX N/A
- MIMI N/A
- EPS Growth
- PLX N/A
- MIMI N/A
- EPS
- PLX 0.04
- MIMI 0.04
- Revenue
- PLX $53,399,000.00
- MIMI $4,248,548.00
- Revenue This Year
- PLX $65.02
- MIMI N/A
- Revenue Next Year
- PLX $57.34
- MIMI N/A
- P/E Ratio
- PLX $79.67
- MIMI $113.89
- Revenue Growth
- PLX N/A
- MIMI 63.94
- 52 Week Low
- PLX $0.82
- MIMI $3.36
- 52 Week High
- PLX $3.10
- MIMI $6.84
- Technical
- Relative Strength Index (RSI)
- PLX 56.85
- MIMI N/A
- Support Level
- PLX $2.70
- MIMI N/A
- Resistance Level
- PLX $2.64
- MIMI N/A
- Average True Range (ATR)
- PLX 0.17
- MIMI 0.00
- MACD
- PLX -0.01
- MIMI 0.00
- Stochastic Oscillator
- PLX 61.67
- MIMI 0.00
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About MIMI MINT INCORPORATION LIMITED
Mint Inc Ltd is a Hong Kong-based interior design and fit-out works provider. It strategically focuses on providing integrated and industry-specific interior design and fit-out works for commercial properties. The company's work encompasses offices of different industries and various kinds of retail stores to reflect its customers' corporate values and conceptualize its customers' brands. Its commercial projects cover internationally-renowned retail stores, food and beverage outlet chains, offices, and other premises of a charitable organization in Hong Kong. It also provides integrated interior design and fit-out works for luxury residential properties to enhance the interior space's aesthetics and functionality.